
Novel Nanobody for Osteoarthritis Enters Clinical Development
Ablynx will receive EUR15 million in milestone payment following Merck’s decision to advance ALX-1141 into clinical development. The nanobody was developed by Ablynx under a 2011 collaboration between both parties.
Ablynx, a biopharmaceutical company headquartered in Ghent, Belgium,
Ablynx and Merck entered into a collaboration in 2011 to co-discover and co-develop nanobodies against two targets in osteoarthritis. ALX-1141 is the first clinical candidate to emerge from this collaboration. Ablynx will be eligible for approximately EUR120 million in development, regulatory, and commercial milestones plus double-digit tiered royalties upon successful development and approval of the product.
“Obtaining preclinical proof-of-concept was an important milestone in this collaboration,” Edwin Moses, CEO of Ablynx, commented in a
Ablynx specializes in the development of nanobodies, which are proprietary therapeutic proteins based on single-domain antibody fragments. Nanobodies combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. The company has more than 45 proprietary and partnered programs in development in various therapeutic areas, including inflammation, hematology, immune-oncology, oncology, and respiratory disease. Ablynx is collaborating with several pharmaceutical companies such as AbbVie, Boehringer Ingelheim, Genzyme, Merck, Novartis, Novo Nordisk, and Taisho Pharmaceuticals.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.